USD
+$0.00
(+0.00%
)At Close (As of Dec 9, 2025)
$4.07M
Market Cap
0.0202
P/E Ratio
48.21
EPS
$14.10
52 Week High
$0.82
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$4.1M |
| Total Revenue | $0 |
| Cost Of Revenue | $4.1M |
| Costof Goods And Services Sold | $4.1M |
| Operating Income | -$11M |
| Selling General And Administrative | $6.4M |
| Research And Development | $4.1M |
| Operating Expenses | $11M |
| Investment Income Net | - |
| Net Interest Income | $16K |
| Interest Income | $46K |
| Interest Expense | $30K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $39K |
| Income Before Tax | -$11M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$11M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$11M |
| Ebitda | -$11M |
| Net Income | -$11M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.5M |
| Total Current Assets | $1.5M |
| Cash And Cash Equivalents At Carrying Value | $865K |
| Cash And Short Term Investments | $865K |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $0 |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $608K |
| Other Non Current Assets | - |
| Total Liabilities | $1.7M |
| Total Current Liabilities | $1.7M |
| Current Accounts Payable | $1.1M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $329K |
| Total Non Current Liabilities | $0 |
| Capital Lease Obligations | $0 |
| Long Term Debt | - |
| Current Long Term Debt | $329K |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $329K |
| Other Current Liabilities | $211K |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$212K |
| Treasury Stock | - |
| Retained Earnings | -$217M |
| Common Stock | $13K |
| Common Stock Shares Outstanding | $6.6M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$4.1M |
| Total Revenue | $0 |
| Cost Of Revenue | $4.1M |
| Costof Goods And Services Sold | $4.1M |
| Operating Income | -$11M |
| Selling General And Administrative | $6.4M |
| Research And Development | $4.1M |
| Operating Expenses | $11M |
| Investment Income Net | - |
| Net Interest Income | $16K |
| Interest Income | $46K |
| Interest Expense | $30K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $39K |
| Income Before Tax | -$11M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$11M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$11M |
| Ebitda | -$11M |
| Net Income | -$11M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Oragenics, Inc. is a biotechnology firm headquartered in Tampa, Florida, dedicated to the development of innovative therapies and antibiotics targeting infectious diseases, particularly those caused by antibiotic-resistant bacteria. The company leverages its proprietary technologies to create novel drug candidates aimed at addressing pressing healthcare challenges. Committed to advancing public health, Oragenics is strategically enhancing its pipeline through partnerships and research initiatives, positioning itself as a key player in the global fight against infectious diseases and improving treatment options.